Luxturna (Voretigene Neparvovec-Rzyl)
Customize your policy alerts
Sign up for UnitedHealthcare Policy CS2026D0064Q alerts
Get alerted when Policy CS2026D0064Q changes without checking for updates manually.
Monitor payer policy activity
This UnitedHealthcare Community Plan Medical Benefit Drug Policy governs prior authorization and medical-necessity coverage for Luxturna, a gene therapy for patients with confirmed biallelic RPE65 mutation-associated inherited retinal dystrophy, subject to state-specific policy exceptions and applicable benefit requirements.
The Background, Clinical Evidence, and References sections were updated to reflect the most current information.
The prior policy version CS2026D0064P was archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.